Isofol Medical AB (SE:ISOFOL)
:ISOFOL
Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.72
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr214.73M
Enterprise Valuekr172.74M
Total Cash (Recent Filing)kr126.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageHaving no recorded debt across 2023–2025 materially lowers financial distress risk for a pre-commercial biotech. This structural strength preserves optionality to raise equity or negotiate partnerships on better terms, supporting program continuity during long development cycles.
Improved Cash Burn DisciplineOperating cash outflows have materially declined versus earlier years, indicating tighter spending and more efficient R&D execution. Sustained lower burn extends runway, reduces frequency of dilutive financings and strengthens the firm’s ability to advance programs through clinical milestones.
Focused Oncology R&D NicheA clear strategic focus on chemo-adjunct oncology therapies concentrates resources and expertise, making the pipeline easier to evaluate and partner with larger pharma. This specialization aligns with persistent, structural demand in oncology and supports durable collaboration opportunities.
Bears Say
No Revenue BaseAbsence of recurring revenue leaves the company fully dependent on external capital to fund operations. Without commercial receipts, management must continually secure financing to sustain trials and development, increasing dilution risk and constraining long-term self-sufficiency.
Persistent Large Losses And Cash BurnSubstantial annual losses and ongoing negative operating cash flow steadily erode resources and require regular funding rounds. Over time this pressure can force program prioritization, slow development timelines, and raise the cost or terms of new capital, hampering strategic flexibility.
Eroded Equity CushionA marked decline in shareholders' equity reflects accumulated losses and reduces the firm’s capital buffer. Lower equity limits borrowing capacity, increases vulnerability to adverse events, and amplifies the dilutive impact of future financing, weakening long-term balance sheet resilience.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.72 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr214.73M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 18 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -kr0.045 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.045.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.045 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―